GlycoZym ApS
Records under this name other than patents GlycoZym ApS holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,635,461 | UDP-N-acetylglucosamine: galactose-&bgr;1, 3-N-acetylgalactosamine-&agr;-R/(GlcNAc to GalNAc) &bgr;1,6-N-acetylglucosaminyltransferase, C2GnT3 Formerly held Term ended Term ended Aug 24, 2020 · USPTO record | Term ended | Term ended Aug 24, 2020 | USPTO record |
| US 7,381,554 | UDP-N-acetylglucosamine: galactose-β1,3-N-acetylgalactosamine-α-R/N-acetylglucosamine-β1,3-N-acetylgalactosamine-α-R (GlcNAc to GalNAc) β1,6-N-acetylglucosaminyltransferase, C2/4GnT Formerly held Lapsed on the fee record Ended Jun 3, 2020 · USPTO record | Lapsed on the fee record | Ended Jun 3, 2020 | USPTO record |
| US 7,338,932 | Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments Formerly held Lapsed on the fee record Ended Mar 4, 2020 · USPTO record | Lapsed on the fee record | Ended Mar 4, 2020 | USPTO record |
| US 7,374,919 | UDP-galactose: β-N-acetyl-glucosamine β-1,4-galactosyltransferase, β4Gal-T2 Formerly held Term ended Term ended May 5, 2019 · USPTO record | Term ended | Term ended May 5, 2019 | USPTO record |
| US 7,115,404 | UDP-galactose: β-D-galactose-R 4-α-D-galac-tosyltransferase, α4Gal-T1 Formerly held Lapsed on the fee record Ended Oct 3, 2018 · USPTO record | Lapsed on the fee record | Ended Oct 3, 2018 | USPTO record |
| US 7,097,994 | UDP-N-acetylglucosamine:galactose-β1,3-N-acetylgalactosamine-α-R/ (GlcNAc to GaINAc) β1-6 N-acetylglucosaminyltransferase, C2GnT3 Formerly held Lapsed on the fee record Ended Aug 29, 2018 · USPTO record | Lapsed on the fee record | Ended Aug 29, 2018 | USPTO record |
| US 7,094,887 | UDP-N-acetylglucosamine: galactose-β1,3-N-acetylgalactosamine-α-R(GlcNAc to GalNAc) β1,6-N-acetylglucosaminyltransferase, C2GnT3 Formerly held Lapsed on the fee record Ended Aug 22, 2018 · USPTO record | Lapsed on the fee record | Ended Aug 22, 2018 | USPTO record |
| US 7,078,206 | UDP-N-acetylglucosamine: galactose-β1,3-N-acetylgalactosamine-α-R/ (GlcNAc to GalNAc) β1,6N-acetylglucosaminyltransferase, C2GnT3 Formerly held Lapsed on the fee record Ended Jul 18, 2018 · USPTO record | Lapsed on the fee record | Ended Jul 18, 2018 | USPTO record |
| US 6,558,934 | UDP-galactose: &bgr;-N-acetyl-glucosamine &bgr;-1,4-galactosyl-transferase, &bgr;4Gal-T2 Formerly held Term ended Term ended Jul 17, 2018 · USPTO record | Term ended | Term ended Jul 17, 2018 | USPTO record |
| US 7,670,816 | UDP-galactose:β-D-galactose-R 4-α-D-galactosyltransferase, α4gal-T1 Formerly held Lapsed on the fee record Ended Mar 2, 2018 · USPTO record | Lapsed on the fee record | Ended Mar 2, 2018 | USPTO record |